Cargando…
Histamine‐2 (H(2)) antagonists can be safely removed from standard paclitaxel premedication regimens
AIMS: The aim of this study is to investigate the rates of hypersensitivity reactions (HSRs) in patients receiving paclitaxel chemotherapy, with and without a histamine‐2 (H(2)) antagonists. METHOD: This prospective, multi‐centre, cohort study compared patients receiving paclitaxel treated with prem...
Autores principales: | Foreman, Emma, Polwart, Calum, Walker, Andrew, Chambers, Pinkie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545865/ https://www.ncbi.nlm.nih.gov/pubmed/35470452 http://dx.doi.org/10.1111/bcp.15363 |
Ejemplares similares
-
No need for H(2)-antagonists in premedication regimens for paclitaxel infusions: less is more
por: Gelderblom, Hans, et al.
Publicado: (2021) -
Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens
por: Kloover, J S, et al.
Publicado: (2004) -
Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer
por: Barroso‐Sousa, Romualdo, et al.
Publicado: (2021) -
Histamine antagonists promote cancer immunosurveillance
por: Liu, Peng, et al.
Publicado: (2023) -
Histamine and Skin Barrier: Are Histamine Antagonists Useful for the Prevention or Treatment of Atopic Dermatitis?
por: De Benedetto, Anna, et al.
Publicado: (2015)